Tags

Type your tag names separated by a space and hit enter

Lack of efficacy of alpha-lipoic acid in burning mouth syndrome: a double-blind, randomized, placebo-controlled study.
Eur J Pain 2009; 13(5):492-6EJ

Abstract

BACKGROUND

A systematic review from the Cochrane Collaboration stated that alpha-lipoic acid (ALA) may help in the management of burning mouth syndrome (BMS). Because all of the data on ALA came from a single group, it has been stressed that its effectiveness should be reproduced in other populations.

AIM

A double-blind, randomized, placebo-controlled study, including two test groups (Group A and Group B) and one control group (Group C), was carried out to evaluate the efficacy of systemic ALA (400 mg) and ALA (400 mg) plus vitamins in the treatment of BMS.

METHODS

Sixty-six patients (54 females and 12 males) were included in an 8-week trial. Symptoms were evaluated by using a visual analogue scale (VAS) and the McGill Pain Questionnaire (MPQ) at 0, 2, 4, 8 and 16 weeks.

RESULTS

Fifty-two patients (43 females and 9 males, aged 67.3+/-11.9 years) completed the study. All three groups had significant reductions in the VAS score and in the mixed affective/evaluative subscale of the MPQ; the responders' rate (at least 50% improvement in the VAS score) was about 30%. No significant differences were observed among the groups either in the response rate or in the mean latency of the therapeutic effect.

CONCLUSIONS

The fairly high placebo effect observed is very similar to data obtained from patients affected by atypical facial pain. This study failed to support a role for ALA in the treatment of BMS, and further investigations are needed to identify the cause of BMS in order to develop efficacious therapies.

Authors+Show Affiliations

Department of Biomedical Sciences and Human Oncology, Oral Medicine Section, University of Turin, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

18675569

Citation

Carbone, Mario, et al. "Lack of Efficacy of Alpha-lipoic Acid in Burning Mouth Syndrome: a Double-blind, Randomized, Placebo-controlled Study." European Journal of Pain (London, England), vol. 13, no. 5, 2009, pp. 492-6.
Carbone M, Pentenero M, Carrozzo M, et al. Lack of efficacy of alpha-lipoic acid in burning mouth syndrome: a double-blind, randomized, placebo-controlled study. Eur J Pain. 2009;13(5):492-6.
Carbone, M., Pentenero, M., Carrozzo, M., Ippolito, A., & Gandolfo, S. (2009). Lack of efficacy of alpha-lipoic acid in burning mouth syndrome: a double-blind, randomized, placebo-controlled study. European Journal of Pain (London, England), 13(5), pp. 492-6. doi:10.1016/j.ejpain.2008.06.004.
Carbone M, et al. Lack of Efficacy of Alpha-lipoic Acid in Burning Mouth Syndrome: a Double-blind, Randomized, Placebo-controlled Study. Eur J Pain. 2009;13(5):492-6. PubMed PMID: 18675569.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lack of efficacy of alpha-lipoic acid in burning mouth syndrome: a double-blind, randomized, placebo-controlled study. AU - Carbone,Mario, AU - Pentenero,Monica, AU - Carrozzo,Marco, AU - Ippolito,Alessio, AU - Gandolfo,Sergio, Y1 - 2008/12/09/ PY - 2008/01/27/received PY - 2008/05/26/revised PY - 2008/06/07/accepted PY - 2008/8/5/pubmed PY - 2009/7/16/medline PY - 2008/8/5/entrez SP - 492 EP - 6 JF - European journal of pain (London, England) JO - Eur J Pain VL - 13 IS - 5 N2 - BACKGROUND: A systematic review from the Cochrane Collaboration stated that alpha-lipoic acid (ALA) may help in the management of burning mouth syndrome (BMS). Because all of the data on ALA came from a single group, it has been stressed that its effectiveness should be reproduced in other populations. AIM: A double-blind, randomized, placebo-controlled study, including two test groups (Group A and Group B) and one control group (Group C), was carried out to evaluate the efficacy of systemic ALA (400 mg) and ALA (400 mg) plus vitamins in the treatment of BMS. METHODS: Sixty-six patients (54 females and 12 males) were included in an 8-week trial. Symptoms were evaluated by using a visual analogue scale (VAS) and the McGill Pain Questionnaire (MPQ) at 0, 2, 4, 8 and 16 weeks. RESULTS: Fifty-two patients (43 females and 9 males, aged 67.3+/-11.9 years) completed the study. All three groups had significant reductions in the VAS score and in the mixed affective/evaluative subscale of the MPQ; the responders' rate (at least 50% improvement in the VAS score) was about 30%. No significant differences were observed among the groups either in the response rate or in the mean latency of the therapeutic effect. CONCLUSIONS: The fairly high placebo effect observed is very similar to data obtained from patients affected by atypical facial pain. This study failed to support a role for ALA in the treatment of BMS, and further investigations are needed to identify the cause of BMS in order to develop efficacious therapies. SN - 1532-2149 UR - https://www.unboundmedicine.com/medline/citation/18675569/Lack_of_efficacy_of_alpha_lipoic_acid_in_burning_mouth_syndrome:_a_double_blind_randomized_placebo_controlled_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1090-3801(08)00138-9 DB - PRIME DP - Unbound Medicine ER -